SCHEMBL23964267

SCHEMBL23964267

Cc1ncnc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)c1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.64
LMNA P02545 2/20 0.64
MAPK1 P28482 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
HTT P42858 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
DRD4 P21917 16/20 0.62
DRD2 P14416 2/20 0.60
HTR1A P08908 1/20 0.59
ADRA2C P18825 1/20 0.59
HTR2A P28223 1/20 0.59
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
CYP3A4 P08684 1/20 0.58
ALOX15 P16050 1/20 0.58
OPRK1 P41145 1/20 0.58
SIGMAR1 Q99720 1/20 0.58
HSD17B10 Q99714 1/20 0.58
GRM2 Q14416 1/20 0.57
NPC1 O15118 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041193 1.00 USP2 (0.64) USP2LMNAMAPK1NPSR1HTT
SCHEMBL23964274 0.82 RPS6KB1 (0.69) USP2LMNAMAPK1NPSR1HTT
SCHEMBL30042095 0.82 RPS6KB1 (0.69) USP2LMNAMAPK1NPSR1HTT
SCHEMBL4804468 0.81 DRD4 (0.76) HTTDRD4DRD2HTR1AADRA2C
SCHEMBL23964137 0.80 USP2 (0.57) USP2LMNAMAPK1NPSR1HTT
SCHEMBL5157052 0.80 HTT (0.84) HTTDRD4DRD2HTR1AADRA2C
SCHEMBL23964201 0.80 HRH4 (0.58) USP2LMNAMAPK1NPSR1HTT
SCHEMBL30041258 0.80 HRH4 (0.58) USP2LMNAMAPK1NPSR1HTT
SCHEMBL4809160 0.77 DRD4 (1.00) HTTDRD4DRD2ALDH1A1KDM4E
SCHEMBL31737287 0.76 RECQL (0.57) LMNAMAPK1NPSR1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 USP2 4691/4885LMNA 575/4885MAPK1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.